latest news releases from the newsroom
Bioheart Announces Plans to Launch Clinical Trials in Europe and the USA for Second-generation Cell Therapy for Treating Advanced Heart Failure
SUNRISE, Fla., Jan. 12, 2009 (GLOBE NEWSWIRE) -- Bioheart, Inc. (Nasdaq:BHRT) announced today that it plans to conduct clinical trials for its second-generation MyoCell SDF-1 myogenic cell composition for treating advanced heart failure. The company believes that it may be able to fund these trials to a large extent with grant funding, which will be non-dilutive to the company's investors. Earlier this year, Bioheart approached the National Heart, Lung and Blood Institute of the National Institutes of Health to discuss the possibility of their Cardiovascular Cell Therapy Research Network Centers to participate in these new clinical trials.
SenoRx Announces Fourth Quarter and Fiscal Year 2008 Webcast and Conference Call
IRVINE, Calif., Jan. 12, 2009 (GLOBE NEWSWIRE) -- SenoRx Inc. (Nasdaq:SENO) today announced it will host its investor conference call to review its Q4/FY2008 financial results and guidance for 2009 on Tuesday, February 24 at 8:00 a.m. PST (11:00 a.m. EST). The call will be open to all investors live via the Investor Relations section of the SenoRx web site at http://investor.senorx.com/events.cfm. A replay of the call will be available on the company's web site approximately 90 minutes after the call concludes. It will also be available to be downloaded as a podcast. SenoRx's financial results press release is expected to be released after market close on Monday, February 23.
Transmeridian Exploration, Inc.
Transmeridian Exploration Incorporated Secures Short-Term Funding and Announces Management Changes
HOUSTON, Jan. 12, 2009 (GLOBE NEWSWIRE) -- Transmeridian Exploration Incorporated (Pink Sheets:TMYE) ("Transmeridian") today announced that Lorrie T. Olivier has resigned his position as Chief Executive Officer and has stepped down as Chairman of Transmeridian's Board of Directors, although he retains his membership on the Board. In addition, Gary Neus and Fred Zeidman, current members of the Transmeridian Board, have agreed to accept positions as Co-Chief Restructuring Officers and Mr. Zeidman will assume Chairmanship of the Board. In their capacities as Co-Chief Restructuring Officers, Messrs. Neus and Zeidman will exercise the entire executive management function over all of Transmeridian's operations and assets, including the on-going efforts to effect a sale or other transaction involving Transmeridian, its indirect wholly owned subsidiary, JSC Caspi Neft TME ("Caspi Neft"), and/or its major asset, the South Alibek field in Kazakhstan.